Related Experiment Video
Updated: Sep 1, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
How I treat Parkinson's disease
Egberto Reis Barbosa1, João Carlos Papaterra Limongi1, Hsin Fen Chien1
1Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, Grupo de Distúrbios do Movimento, São Paulo, SP, Brazil.
Arquivos De Neuro-Psiquiatria
|August 17, 2022
Summary
Tailored treatment and regular exercise are key for Parkinson's disease (PD) management. Strategies should prioritize functional capacity and quality of life across all disease stages, from early to advanced.
Area of Science:
- Neurology
- Neurodegenerative Diseases
Background:
- Parkinson's disease (PD) is a complex neurodegenerative disorder.
- Effective treatment strategies across all disease stages are vital for managing quality of life and preventing complications.
Purpose of the Study:
- To review current treatment approaches for Parkinson's disease.
- To cover therapeutic interventions from early to advanced stages of the condition.
Main Methods:
- A comprehensive literature review was performed.
- The review focused on the treatment of Parkinson's disease at different stages of progression.
Main Results:
- Regular exercise is recommended for all individuals diagnosed with PD.
- Early-stage treatment involves optimizing levodopa dosage to maximize function while minimizing risks like dyskinesias and impulse control disorders.
- In moderate to advanced stages, managing motor fluctuations and treatment complications is crucial for maintaining quality of life. Rehabilitation programs can improve motor symptoms at any stage.
Conclusions:
- Treatment decisions for PD must consider disease progression, risk factors for complications, and potential side effects.
- The primary goals of Parkinson's disease treatment are to maintain functional capacity and enhance quality of life throughout the disease course.
Related Concept Videos
01:24Parkinson's Disease: Treatment
363
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
363
01:15Parkinson's Disease: Overview
686
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
686
01:22Alzheimer's Disease: Treatment
254
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
254
01:28Drug Therapy
92
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
92
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
235
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
235
01:37Neural Regulation
39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K